Characterization of Adeno-Associated Viral assemblies on an Ultra-High Mass Range Hybrid Quadrupole-**Orbitrap Mass Spectrometer**

Kristina Srzentić¹, Eugen Damoc², Marc Günder¹ ¹Thermo Fisher Scientific, Reinach, Switzerland ²Thermo Fisher Scientific, Bremen, Germany

ABSTRACT

Purpose: Evaluate the performance of the Thermo Scientific[™] Q Exactive[™] UHMR hybrid quadrupole-Orbitrap[™] mass spectrometer for intact mass analysis of viral assemblies under near native conditions and LC-MS intact and top-down mass spectrometry for AAV protein subunit analysis

Methods: (1) Intact mass analysis under native conditions using static nanospray, (2) Top-down analysis using RP LC-MS/MS

Results: Results demonstrate excellent performance of the Q Exactive UHMR mass spectrometer for analysis of AAV assemblies under near native and denaturing conditions.

INTRODUCTION

Adeno-associated viral capsids (AAVs) are rapidly emerging delivery vehicles used to transport drugs into patients. In-depth knowledge about key structural characteristics of constituent capsid proteins, their proteoforms and their stoichiometries in viral assembly is critical for new modalities development in gene therapy and finding appropriate patient treatments. Mass spectrometry-based approaches can offer accurate intact mass determination and allows elucidation of intact proteoforms, afforded high resolution accurate mass measurement. In addition, analysis of product ions upon fragmentation at MS2 level can increase confidence in assigned proteoforms and oftentimes confirm their exact location within the amino acid sequence. Here we demonstrate the utility of an Orbitrap-based LC-MS platform to characterize the denatured AAV and their associated proteins with high sensitivity and mass accuracy.

MATERIALS AND METHODS

Sample Preparation

AAV serotypes 2 and 6 were expressed and harvested in HEK293 cells. For intact mass measurement under near native conditions, AAV2 and AAV6 were buffer exchanged into 100 mM ammonium acetate using 30 kDa MWCO (Millipore-Sigma). For capsid protein analysis, AAV6 was additionally incubated with acid to generate subunits.

Liquid Chromatography and Mass Spectrometry

Intact mass analysis of viral assembly under near native conditions was performed by directly infusing the sample using coated emitters and static NanoFlex source. For intact capsid protein analysis under denatured conditions, and subsequent top-down analysis, RP LC-MS separation was accomplished using a Thermo Scientific[™] Vanquish[™] Horizon UHPLC system. For relative quantitation of empty vs full capsid, IEX separation was performed on a Thermo Scientific™ Vanguish[™] Flex UHPLC system equipped with a Thermo Scientific[™] Vanguish[™] fluorescence detector. All intact MS and top-down MS measurements were carried out on a Q Exactive UHMR hybrid quadrupole-Orbitrap mass spectrometer.

Figure 1. General workflow for analysis of AAV viral assembly under near native conditions and analysis of AAV VP subunits analysis under denaturing conditions



Data Analysis

Thermo Scientific[™] BioPharma Finder[™] 4.1 software was used for intact deconvolution and top-down analysis

RESULTS

MS analysis of intact AAV2 under native conditions

Native MS analysis of intact AAV2 using static nanospray revealed the presence of at least three different forms with the following VP1:VP2:VP3 stoichiometries: 5:5:50, 5:6:49, and 5:7:48.

Figure 2. Native MS spectrum of AAV2 viral assembly showing baseline resolved 5:5:50, 5:6:49 and 5:7:48 forms



IEX-FLD analysis of intact AAV6

IEX-FLD analysis of the intact AAV sample revealed the presence of empty and cargo-loaded capsid with a relative ratio for empty:full capsid of ~64% :36%.

Figure 3. IEX-FLD elution profile of empty and cargo=loaded capsid for AAV6 serotype



MS analysis of AAV6 capsid proteins

RP LC-MS analysis of AAV6 serotype resulted in identification of several proteoforms of viral particle (VP) subunits comprised of truncated species in combination with a variety of post-translational modifications (PTMs), such as Nterminal acetylation and phospohorylation at serine (S) and threonine (T) sites in VP2. Integrated peak areas from total ion chromatogram (TIC) were used for relative quantitation. Relative abundances of the detected components were calculated against the integrated peak area of VP3, assigned as 100%. Determined ratio between detected subunits, VP1, VP2 and VP3 was 7:5:48, respectively.



Figure 5. MS spectra of VP1, VP2 and VP3 subunits of AAV6 AAV6 VP3 **3.9 ppm** 59518.48 AAV6 VP1 0.3 ppm 81321.65 59400 59500 59600 81200 81400 Mass 3000 4000 1000 2000 4000 1000 2000 *m/z* 3000 AAV6 VP2 2.9 ppm 66095.14 66000 66100 Mass 1000 2000 3000 m/z

Top-Down analysis of VP2 from AAV6

Top-down analysis under denaturing conditions was performed using All Ion Fragmentation (AIF) measurements on the Q Exactive UHMR instrument. Deploying AIF allowed for selection of entire charge state envelope of all major subunits, as well as truncated species, clip and proteoforms of VPs, thus enhancing fragmentation efficiency using HCD. Absolute collisional energy was set to 18, 20 and 22V in three separate acquisitions. The resulting LC-MS/MS spectra were searched with BioPharma Finder 4.1 and fragment ions matched using 10 ppm mass accuracy tolerance. In addition, HCD experiments resulted in well sequenced termini for all species. Presence of Ser-11 and Thr-56 phosphorylations in VP2 was confirmed by series of *b*-ions (see Figures 7A and 7B).



N APGKKRPVEQSPQEPDSSSGIGKTG

SE QIQ PAKKRLNFGQTGDISIEISIVIPDIPQIPIL

🔊 G E P P A T P A A V G P T T M A S G G G A P M A D 🚿

76 N N E G A D G V G N A S G N W H C D S T W L G D R 30

101 VITTSTRTWALPTYNNHLYKQISSA 335

126 STGASNDNHYFGYSTPWGYFDFNRF 180

181 H C H F S P R D W O R L I N N N W G F R P K R L N 176

176 F K L F N I Q V K E V T T N D G V T T I A N N L T 20

NOM STVQVFSDSEYQLPYVLGSAHQGCL 2005

226 P F F A D V F M I P Q Y G Y L T L N N G S Q A V 250

258 G R S S F Y C L E Y F P S Q M L R T G N N F T F S 278

276 Y T F E D V P F H S S Y A H S Q S L D R L M N P L 300

308. I D Q Y L Y Y L N R T Q N Q S G S A Q N K D L L F 385

326 S R G S P A G M S V Q P K N W L P G P C Y R Q Q R 350

35% V S K T K T D N N N S N F T W T G A S K Y N L N G 375

3776 RESIINPGTAMASHKDDKDKFFPMS 400

436 E E I K A T N P V A T E R F G T V A V N L Q[S[S[S 430

ENTIDLE ALT G D V H V M G A L P G M V W Q D R D V Y 655 555 L Q G P I W A K I P HLT D G H F H P S P L M G G F 500

508. G L K H P P P Q I L I K N T P VLP A NLPLP A E F S 525

1886 A T K F A S F I T QIYISITIGIQ VISIV E I E W E L Q 550 KENSKRWNPEVQLYTLSNYLAKSANVLDLF

METIVIDININIGILIYIT ELP R PLI GITIRIY L T R P L C

Figure 6. Graphical fragments map of VP2

fragment

ion types

Data processed using BioPharma Finder 4.1: minimum required fitter score: 80, S/N = 7, fragment mass tolerance: 10 ppm

Figure 7. AAV6 VP2 phosphorylation sites mapping using Top-Down analysis. (A) Phosphorylation of Ser-11, (B) Phosphorylation of Thr-56





CONCLUSIONS

- Intact mass measurement under near-native conditions revealed presence of empty and cargoloaded capsid in approximate ratio of 1:5.
- For the AAV2 we determined the presence of at least three different forms with the following VP1:VP2:VP3 stoichiometries: 5:5:50, 5:6:49, and 5:7:48.
- Time-resolved analysis of AAV6 serotype resulted in identification of several proteoforms of viral particle (VP) subunits comprised of truncated species in combination with a variety of posttranslational modifications (PTMs), such as N-terminal acetylation and phosphorylation at serine (S) and threonine (T) sites in VP2.
- Intact mass analysis of VP subunits using 16 ms transient allowed mass determination with mass accuracy below 4 ppm.
- N-terminal acetylation of VP1 and VP3 subunits was directly confirmed from intact mass measurement due to excellent mass accuracy and spectral clarity obtained on Orbitrap-based mass spectrometer.
- Presence of phosphorylation PTM in VP2 was confirmed for T56 by series of *b*-ions, and in case S11 of also localized by adjacent b_{12} -ion.

ACKNOWLEDGEMENTS

Authors would like to thank Julia Baek, Katy Irvin and Steven Milian for providing AAV samples, and wide team at Thermo Fisher Scientific who helped with method developments

TRADEMARKS/LICENSING

© 2021 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries. This information is not intended to encourage use of these products in any manner that might infringe the intellectual property rights of others.

PO66125 EN0921S



Thermo Fisher SCIENTIFIC

A P G K K R P V]E]Q]S]P Q E]P D S]S S G I G K T]G] Q]Q P A]K K R L N F G Q T G D]S]E]S]V]P D]P Q]P]L GE]PPA TPA]AVGPTTMASGGGAPMAD N N E G A D G V G N A S G N W H C D S T W L G D R I V I T T S T R T W A L P T Y N N H L Y K QII S S A S T G A S N D N H Y F G Y S T P W G Y F D F N R F IHCHFSPRDWQRLINNNWGFRPKRLN FKLFNIQVKEVTTNDGVTTIANNLT S Τ V Q V F S D S E Y Q L P Y V L G S A H Q G C L P P F P A D V F M I P Q Y G Y L T L N N G S Q A GRSSFYCLEYFPSOMLRTGNNFTFS TFEDVPFHSSYAHSQSLDRLMNPL IDOYLYYLNRTONOSGSAONKDLLF V S K T K T D N N N S N F T W T G A S K Y N L N G R E S I I N P G T A M A S H K D D K D K F F P M S G V M I F G K E S A G A S N T A L D N V M I T D E E E I K A T N P V A T E R F G T V A V N L Q[S[S[S T T D P A T G D V H V M G A L P G M V W Q D R D V Y LQGPIWAKIPHLTDGHFHPSPLMGGF GLKHPPPQILIKNTPVLPANLPLPAEFS ATKFASFITOIYISITIGIO VISIVEIEWELO KENSKRWNPEVQLYTLSNYLAKSANVLDLF TIVIDININGLIYIT EIP R PII GITIRIY L T R P L

thermo scientific